[{"id":"434f2313-9f1f-4287-82bb-2e00944ce448","acronym":"","url":"https://clinicaltrials.gov/study/NCT01881217","created_at":"2021-01-18T08:26:02.192Z","updated_at":"2025-02-25T17:06:51.733Z","phase":"Phase 1","brief_title":"First-in-man Dose Escalation Study of BAY1179470 in Patients With Advanced, Refractory Solid Tumors","source_id_and_acronym":"NCT01881217","lead_sponsor":"Bayer","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 expression • FGFR2b expression","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 expression • FGFR2b expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aprutumab (BAY 1179470)"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 06/28/2013","start_date":" 06/28/2013","primary_txt":" Primary completion: 03/18/2016","primary_completion_date":" 03/18/2016","study_txt":" Completion: 08/16/2016","study_completion_date":" 08/16/2016","last_update_posted":"2017-09-14"}]